

We're taking aim at
chronic disease in America.

And we won't give up
until we conquer.



Today **SPHERIX** research is taking aim at diabetes

SPHERIX research and development: a potent weapon against chronic diseases

Launched in 1967 as a scientific research company, today SPHERIX leverages its scientific and technical expertise through two divisions:


- **Biospherics, Inc**—dedicated to research and product development for innovations in the biotechnology industry resulting in proprietary health, drug, and medical products and processes

It is currently conducting a Phase 3 clinical trial exploring a new treatment for Type 2 diabetes.

- **Spherix Consulting, Inc**—providing advice and expertise in all aspects of drug development, both to its sister division (BIOSPHERICS) and to outside companies




Diabetes is America's fastest-growing epidemic



- Afflicts 23.6 million (7.8% of population)
- Another 5.7 million remain undiagnosed
- Unabated 5% annual increase in incidence since 1990¹
- Unknown cause—genetics, environment, and behavior appear to be factors (e.g., obesity and lack of exercise)¹

Most common form: Type 2 diabetes

- Results from insulin resistance
- Accounts for 90% to 95% of all cases¹
- Most patients gradually lose glycemic control—even with effective oral drugs—as beta cells gradually cease to function due to:
 - Toxicity
 - Increased secretory demand
 - Amyloid deposition and altered cytokine levels
 - Underestimated effect of insulin stimulation



Pre-diabetes now afflicts 57 million people



- Many patients spend years in pre-diabetic state before progressing to Type 2 diabetes
- Blood glucose levels are above normal but below diagnostic level of Type 2 diabetes

Reference: 1. American Diabetes Association, 2009.

The **SPHERIX** pipeline— renewed hope against chronic diseases

Indication	Pre-Clinical	Phase I	Phase II	Phase III	Marketed
Type 2 Diabetes					
Atherosclerosis					
Dyslipidemia					
Metabolic Syndrome					
Obesity					
Diabetes					



SPHERIX® Headquarters

6430 Rockledge Drive
Westmoreland Bldg. #503
Bethesda, MD 20817

Contact: **Robert A. Lodder, PhD, President**

E-mail: info@spherix.com

Phone: **301-897-2564**

Toll Free: **866-SPHERIX (744-3749)**

Fax: **301-897-2567**

Web: www.spherix.com

NASDAQ CM: **SPEX**